UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028089
Receipt number R000032158
Scientific Title Prospective cohort study of medication for inflammatory bowel disease
Date of disclosure of the study information 2017/07/06
Last modified on 2017/07/05 22:25:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective cohort study of medication for inflammatory bowel disease

Acronym

Prospective cohort study of medication for inflammatory bowel disease

Scientific Title

Prospective cohort study of medication for inflammatory bowel disease

Scientific Title:Acronym

Prospective cohort study of medication for inflammatory bowel disease

Region

Japan


Condition

Condition

inflammatory bowel disease

Classification by specialty

Medicine in general Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aimed to evaluate the efficacy and safety of patients treated with inflammatory bowel disease for ulcerative colitis and Crohn's disease patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The rate of clinical efficacy at 8 weeks after initiation of treatment

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1 Ministry of Health, Labor and Welfare Survey Study on Intractable Inflammatory Bowel Disease Disorder Patients newly intervening therapeutically among cases diagnosed as ulcerative colitis or Crohn's disease according to diagnostic criteria.
2 Patient who obtained consent of this study.
3 Patients over 16 years of age.

Key exclusion criteria

1 patients suspected of having intestinal inflammation other than UC and Crohn's disease (infectious enteritis, etc.).
2 Patients with symptomatic digestive tract stenosis.
3 Patient planning resection of colon.
4 Severe infections Patients with complications.
5 Other patients who judged that the physician in charge is inappropriate to incorporate into this study.

Target sample size

600


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Naganuma

Organization

School of Medicine, Keio University

Division name

Gastroenterology and Hepatology

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Email

nagamakoto@keio.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makoto Naganuma

Organization

School of Medicine, Keio University

Division name

Gastroenterology and Hepatology

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Homepage URL


Email

nagamakoto@keio.jp


Sponsor or person

Institute

School of Medicine, Keio University

Institute

Department

Personal name



Funding Source

Organization

School of Medicine, Keio University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 07 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 06 Month 07 Day

Date of IRB


Anticipated trial start date

2017 Year 07 Month 06 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

rate of response and clinical remission, frequency and type of side effects. Albumin, ESR, CRP, WBC, Plt (albumin, CRP, WBC, Plt), the transition of disease activity (partial Mayo score, CDAI), symptomatic transition (stool frequency, nocturia diarrhea, bloody stool, abdominal pain, fever, general evaluation) , Fecal occult blood), transition of endoscopic findings (Mayo score, activity). Side effects, presence or absence of adverse events.


Management information

Registered date

2017 Year 07 Month 05 Day

Last modified on

2017 Year 07 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032158


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name